135 related articles for article (PubMed ID: 22350899)
1. Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
Gallastegui N; Groll M
Methods Mol Biol; 2012; 832():373-90. PubMed ID: 22350899
[TBL] [Abstract][Full Text] [Related]
2. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
3. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
4. [Development and clinical application of novel proteasome inhibitors].
Iida S
Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
[No Abstract] [Full Text] [Related]
5. Second Generation Proteasome Inhibitors in Multiple Myeloma.
Gozzetti A; Papini G; Candi V; Brambilla CZ; Sirianni S; Bocchia M
Anticancer Agents Med Chem; 2017; 17(7):920-926. PubMed ID: 27592543
[TBL] [Abstract][Full Text] [Related]
6. Purification, crystallization, and X-ray analysis of the yeast 20S proteasome.
Groll M; Huber R
Methods Enzymol; 2005; 398():329-36. PubMed ID: 16275340
[TBL] [Abstract][Full Text] [Related]
7. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
[TBL] [Abstract][Full Text] [Related]
8. Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
Gräwert MA; Groll M
Chem Commun (Camb); 2012 Feb; 48(10):1364-78. PubMed ID: 22039589
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
Huber EM; Groll M
Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914.
Huber EM; Heinemeyer W; Groll M
Structure; 2015 Feb; 23(2):407-17. PubMed ID: 25599643
[TBL] [Abstract][Full Text] [Related]
11. [Proteasome inhibitors in cancer therapy].
Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
[TBL] [Abstract][Full Text] [Related]
12. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
Schrader J; Henneberg F; Mata RA; Tittmann K; Schneider TR; Stark H; Bourenkov G; Chari A
Science; 2016 Aug; 353(6299):594-8. PubMed ID: 27493187
[TBL] [Abstract][Full Text] [Related]
13. (-)-Homosalinosporamide A and Its Mode of Proteasome Inhibition: An X-ray Crystallographic Study.
Groll M; Nguyen H; Vellalath S; Romo D
Mar Drugs; 2018 Jul; 16(7):. PubMed ID: 30029468
[TBL] [Abstract][Full Text] [Related]
14. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
15. Innovation in myeloma treatments PARP excellence!
Fonseca R
Blood; 2011 Dec; 118(24):6234-5. PubMed ID: 22161848
[No Abstract] [Full Text] [Related]
16. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
18. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
[TBL] [Abstract][Full Text] [Related]
19. Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A.
Kale AJ; McGlinchey RP; Lechner A; Moore BS
ACS Chem Biol; 2011 Nov; 6(11):1257-64. PubMed ID: 21882868
[TBL] [Abstract][Full Text] [Related]
20. Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition.
Groll M; McArthur KA; Macherla VR; Manam RR; Potts BC
J Med Chem; 2009 Sep; 52(17):5420-8. PubMed ID: 19678642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]